EP4743447A1 - NEW CONNECTIONS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES - Google Patents
NEW CONNECTIONS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASESInfo
- Publication number
- EP4743447A1 EP4743447A1 EP24740175.5A EP24740175A EP4743447A1 EP 4743447 A1 EP4743447 A1 EP 4743447A1 EP 24740175 A EP24740175 A EP 24740175A EP 4743447 A1 EP4743447 A1 EP 4743447A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- treatment
- metabolic diseases
- new connections
- connections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23185489 | 2023-07-14 | ||
| EP24182972 | 2024-06-19 | ||
| PCT/EP2024/069833 WO2025016909A1 (en) | 2023-07-14 | 2024-07-12 | Novel compounds for the treatment of cancer and metabolic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4743447A1 true EP4743447A1 (en) | 2026-05-20 |
Family
ID=91856247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24740175.5A Pending EP4743447A1 (en) | 2023-07-14 | 2024-07-12 | NEW CONNECTIONS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES |
| EP24743789.0A Pending EP4743178A1 (en) | 2023-07-14 | 2024-07-12 | NEW CONNECTIONS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24743789.0A Pending EP4743178A1 (en) | 2023-07-14 | 2024-07-12 | NEW CONNECTIONS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP4743447A1 (en) |
| KR (2) | KR20260040037A (en) |
| CN (2) | CN121568928A (en) |
| AR (2) | AR133250A1 (en) |
| AU (2) | AU2024294886A1 (en) |
| CO (2) | CO2026000332A2 (en) |
| IL (2) | IL325828A (en) |
| TW (2) | TW202519209A (en) |
| WO (2) | WO2025016906A1 (en) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| BRPI0619547A2 (en) * | 2005-12-08 | 2011-10-04 | Novartis Ag | 1,1,3-trioxo-1,2,5-thiadiazolidines, pharmaceutical composition and use thereof |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| AU2020234712B2 (en) | 2019-03-14 | 2025-12-04 | Abbvie Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| MX2022007441A (en) | 2019-12-18 | 2022-09-02 | Calico Life Sciences Llc | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND THEIR METHODS OF USE. |
| WO2021127586A1 (en) | 2019-12-20 | 2021-06-24 | Calico Life Sciences Llc | Protein tyrosine phosphatase degraders and methods of use thereof |
| CN117279913A (en) | 2021-03-11 | 2023-12-22 | 金橘生物科技公司 | Heterocyclic compounds and their uses |
| AU2022397239A1 (en) | 2021-11-23 | 2024-06-06 | Kumquat Biosciences Inc. | Hetero-atom containing compounds and uses thereof |
| CN117658947B (en) * | 2022-09-06 | 2026-03-06 | 杭州中美华东制药有限公司 | 5-(substituted aryl)-1,2,5-thiadiazolin-3-one compounds that inhibit protein tyrosine phosphatase |
-
2024
- 2024-07-12 KR KR1020267004414A patent/KR20260040037A/en active Pending
- 2024-07-12 KR KR1020267004409A patent/KR20260037131A/en active Pending
- 2024-07-12 IL IL325828A patent/IL325828A/en unknown
- 2024-07-12 AU AU2024294886A patent/AU2024294886A1/en active Pending
- 2024-07-12 AR ARP240101826A patent/AR133250A1/en unknown
- 2024-07-12 TW TW113126300A patent/TW202519209A/en unknown
- 2024-07-12 EP EP24740175.5A patent/EP4743447A1/en active Pending
- 2024-07-12 TW TW113126297A patent/TW202519514A/en unknown
- 2024-07-12 AR ARP240101825A patent/AR133249A1/en unknown
- 2024-07-12 WO PCT/EP2024/069828 patent/WO2025016906A1/en not_active Ceased
- 2024-07-12 CN CN202480044245.6A patent/CN121568928A/en active Pending
- 2024-07-12 IL IL325825A patent/IL325825A/en unknown
- 2024-07-12 CN CN202480044349.7A patent/CN121568929A/en active Pending
- 2024-07-12 EP EP24743789.0A patent/EP4743178A1/en active Pending
- 2024-07-12 WO PCT/EP2024/069833 patent/WO2025016909A1/en not_active Ceased
- 2024-07-12 AU AU2024296172A patent/AU2024296172A1/en active Pending
-
2026
- 2026-01-14 CO CONC2026/0000332A patent/CO2026000332A2/en unknown
- 2026-01-15 CO CONC2026/0000413A patent/CO2026000413A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121568929A (en) | 2026-02-24 |
| EP4743178A1 (en) | 2026-05-20 |
| IL325825A (en) | 2026-03-01 |
| TW202519209A (en) | 2025-05-16 |
| IL325828A (en) | 2026-03-01 |
| AR133250A1 (en) | 2025-09-10 |
| AR133249A1 (en) | 2025-09-10 |
| TW202519514A (en) | 2025-05-16 |
| CO2026000332A2 (en) | 2026-02-02 |
| WO2025016909A1 (en) | 2025-01-23 |
| AU2024296172A1 (en) | 2026-03-05 |
| CO2026000413A2 (en) | 2026-02-02 |
| AU2024294886A1 (en) | 2026-03-05 |
| KR20260037131A (en) | 2026-03-17 |
| CN121568928A (en) | 2026-02-24 |
| WO2025016906A1 (en) | 2025-01-23 |
| KR20260040037A (en) | 2026-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4171548A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
| EP4473970A4 (en) | Pharmaceutical composition for the treatment of tumors | |
| EP3976189C0 (en) | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | |
| EP4125846A4 (en) | PYRAZOLYLPROPANMIDE COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF PROSTATE CANCER | |
| EP4337329A4 (en) | COMBINATIONS FOR THE TREATMENT OF CANCER | |
| EP4139454A4 (en) | COMPOSITIONS FOR THE TREATMENT OF CANCER MUTATIONS AND USES THEREOF | |
| EP3990119A4 (en) | METHODS AND COMPOSITIONS USING BRD9 ACTIVATION THERAPIES FOR THE TREATMENT OF CANCER AND RELATED DISEASES | |
| EP3713957A4 (en) | ANTI-CXCL13 ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | |
| EP4151227A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | |
| EP4479390A4 (en) | THIOSTREPTON-INSPIRED COMPOUNDS FOR THE TREATMENT OF CANCER AND THE MANUFACTURING OF THEM | |
| EP4259639A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP4259638A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP4277613A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BREAST CANCER AND METHODS OF USE THEREOF | |
| EP4215531A4 (en) | COMPOUND FOR THE PREVENTION AND TREATMENT OF LIVER DISEASES AND PHARMACEUTICAL USE THEREOF | |
| EP3958863C0 (en) | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF KIDNEY DISEASES | |
| EP4422608A4 (en) | Endoxifen for the treatment of cancer | |
| EP4403182A4 (en) | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER | |
| EP4323001A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP4478887A4 (en) | NEW PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF INSTALLATION | |
| EP4157246C0 (en) | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BREAST CANCER | |
| EP4743178A1 (en) | NEW CONNECTIONS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | |
| EP4119160A4 (en) | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER | |
| EP4119158A4 (en) | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER | |
| EP4561557A4 (en) | Compositions and methods for the treatment of metabolic diseases | |
| EP4138877A4 (en) | TARGETING THE PALMOTYLATION/DEPALMOTYLATION CYCLE FOR THE TREATMENT OF INFLAMMATORY DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |